

course, came here Thursday and wanted us to pass \$700 billion, and they want us to pass this very soon. So “rapidly” sometimes is in the eye of the beholder.

The point is, you’re correct; there was a discrepancy. We think that was not fair. It was not intentional. But Mr. ARCURI, who gave the information to the minority and the information that was on the Web site, was not correct. We think, under those circumstances, in fairness to all, that we ought to redo this, and that’s what we intend to do. And we discussed it with your leadership and we all agreed that that was the right thing to do.

Mr. SESSIONS. Continuing my reservation, I would say to the gentleman that we’re not in any hurry over here in doing it right. The Republican Party is not in a rush, and we would wish for us to do very deliberately that which needs to be done.

Mr. HASTINGS of Washington. Would the gentleman yield?

Mr. SESSIONS. I would yield to the gentleman from Washington.

Mr. HASTINGS of Washington. I appreciate the gentleman yielding.

Mr. Speaker, this is really very, very important because we are at the last days of this session and we know there is a rush to try to get things done. And I understand that it was a book-keeping—it wasn’t intentional. I understand all of that, we’ve been through this before. But the significance of this, and it needs to be understood by this body as we are being asked in the future to make some big decisions, the difference in this little error was \$100 million. It wasn’t small potatoes, so to speak. And I just want to say that the right thing to do—and I hope this is what’s going to happen—is that the Rules Committee goes back upstairs and reports it out correctly so we can have the text. But I think that point needs to be made. And I appreciate the gentleman for yielding.

Mr. HOYER. Would the gentleman yield?

Mr. SESSIONS. I would yield to the gentleman.

Mr. HOYER. I told the gentleman from Washington that’s exactly what I’m trying to do, which is why I thought it best to obviate the vote so we can do exactly what you’ve suggested. I’ve discussed it with your leadership and they’ve agreed. I hope we can do that, and I hope there’s not an objection.

Mr. SESSIONS. Mr. Speaker, I withdraw my reservation.

The SPEAKER pro tempore. Without objection, the vote on adoption of the resolution is vacated.

There was no objection.

Mr. HOYER. Mr. Speaker, I ask unanimous consent that both the vote on the adoption of the rule and the vote on the previous question be vacated.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from Maryland?

There was no objection.

Mr. ARCURI. Mr. Speaker, under the rules, I withdraw House Resolution 1501.

The SPEAKER pro tempore. The resolution is withdrawn.

□ 1545

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Without objection, 5-minute voting will continue.

There was no objection.

UNITED STATES COMMITMENT TO PRESERVATION OF RELIGIOUS AND CULTURAL SITES

The SPEAKER pro tempore. The unfinished business is the vote on the motion to suspend the rules and agree to the concurrent resolution, H. Con. Res. 255, as amended, on which the yeas and nays were ordered.

The Clerk read the title of the concurrent resolution.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from New York (Mr. CROWLEY) that the House suspend the rules and agree to the concurrent resolution, H. Con. Res. 255, as amended.

This will be a 5-minute vote.

The vote was taken by electronic device, and there were—yeas 414, nays 1, not voting 18, as follows:

[Roll No. 641]

YEAS—414

Abercrombie	Brown-Waite,	Davis (KY)	Garrett (NJ)	Lynch	Rothman
Ackerman	Ginny	Davis, Lincoln	Gerlach	Mack	Royalball-Allard
Aderholt	Buchanan	Davis, Tom	Giffords	Mahoney (FL)	Royce
Akin	Burgess	Deal (GA)	Gilchrest	Maloney (NY)	Ruppersberger
Alexander	Burton (IN)	DeFazio	Gillibrand	Manzullo	Rush
Allen	Butterfield	DeGette	Gingrey	Marchant	Ryan (OH)
Altmire	Buyer	Delahunt	Gohmert	Markey	Ryan (WI)
Andrews	Calvert	DeLauro	Gonzalez	Marshall	Salazar
Arcuri	Camp (MI)	Dent	Goode	Matheson	Sali
Baca	Campbell (CA)	Diaz-Balart, L.	Goodlatte	Matsui	Sánchez, Linda
Bachmann	Cannon	Diaz-Balart, M.	Gordon	McCarthy (CA)	T.
Baird	Cantor	Dicks	Granger	McCarthy (NY)	Sanchez, Loretta
Baldwin	Capito	Dingell	Graves	McCaul (TX)	Sarbanes
Barrett (SC)	Capps	Doggett	Green, Al	McCollum (MN)	Saxton
Barrow	Capuano	Donnelly	Green, Gene	McCotter	Scalise
Bartlett (MD)	Cardoza	Doolittle	Grijalva	McCrery	Schakowsky
Barton (TX)	Carnahan	Doyle	Gutierrez	McDermott	Schiff
Bean	Carney	Drake	Hall (NY)	McGovern	Schmidt
Becerra	Carson	Dreier	Hall (TX)	McHenry	Schwartz
Berkley	Carter	Duncan	Hare	McHugh	Scott (GA)
Berman	Castle	Edwards (MD)	Harman	McIntyre	Scott (VA)
Berry	Castor	Edwards (TX)	Hastings (WA)	McKeon	Sensenbrenner
Biggert	Cazayoux	Ehlers	Hayes	McMorris	Serrano
Billray	Chabot	Ellison	Heller	Rodgers	Sessions
Bilirakis	Chandler	Ellsworth	Hensarling	McNerney	Sestak
Bishop (GA)	Childers	Emanuel	Herger	McNulty	Shadegg
Bishop (NY)	Clarke	Emerson	Herseth Sandlin	Meek (FL)	Shays
Bishop (UT)	Clay	Engel	Higgins	Meeks (NY)	Shea-Porter
Blackburn	Cleaver	English (PA)	Hill	Melancon	Sherman
Blumenauer	Clyburn	Eshoo	Hinchev	Mica	Shimkus
Blunt	Coble	Etheridge	Hinojosa	Michaud	Shuster
Bonner	Cohen	Fallin	Hirono	Miller (MI)	Simpson
Bono Mack	Cole (OK)	Farr	Hobson	Miller (NC)	Sires
Boozman	Conaway	Fattah	Hodes	Miller, Gary	Skelton
Boren	Cooper	Feeney	Hoekstra	Miller, George	Slaughter
Boswell	Costa	Ferguson	Holden	Mitchell	Smith (NE)
Boucher	Costello	Filner	Holt	Mollohan	Smith (NJ)
Boustany	Courtney	Flake	Honda	Moore (KS)	Smith (TX)
Boyd (FL)	Crenshaw	Forbes	Hooley	Moore (WI)	Smith (WA)
Boyd (KS)	Crowley	Fortenberry	Hulshof	Moran (KS)	Snyder
Brady (PA)	Cuellar	Fossella	Hunter	Moran (VA)	Solis
Brady (TX)	Culberson	Foster	Inglis (SC)	Murphy (CT)	Space
Bralley (IA)	Cummings	Foxo	Insee	Murphy, Patrick	Speier
Broun (GA)	Davis (AL)	Franks (AZ)	Issa	Murphy, Tim	Spratt
Brown (SC)	Davis (CA)	Frelinghuysen	Issa	Murtha	Stark
Brown, Corrine	Davis (IL)	Gallegly	Jackson (IL)	Musgrave	Stearns
			Jackson-Lee (TX)	Myrick	Stupak
			Jefferson	Nadler	Sullivan
			Johnson (GA)	Neal (MA)	Sutton
			Johnson (IL)	Neugebauer	Tancredo
			Johnson, E. B.	Nunes	Tanner
			Johnson, Sam	Oberstar	Tauscher
			Jones (NC)	Obey	Taylor
			Jordan	Olver	Terry
			Kagen	Ortiz	Thompson (CA)
			Kanjorski	Pallone	Thompson (MS)
			Kaptur	Pascrell	Thornberry
			Keller	Pastor	Tiahrt
			Kennedy	Payne	Tiberi
			Kildee	Pearce	Tierney
			Kilpatrick	Pence	Towns
			Kind	Perlmutter	Tsongas
			King (IA)	Peterson (MN)	Turner
			King (NY)	Peterson (PA)	Udall (NM)
			Kingston	Petri	Upton
			Kirk	Pickering	Van Hollen
			Klein (FL)	Pitts	Velázquez
			Kline (MN)	Platts	Visclosky
			Knollenberg	Poe	Walberg
			Kucinich	Pomeroy	Walden (OR)
			Kuhl (NY)	Porter	Walsh (NY)
			LaHood	Price (GA)	Walz (MN)
			Lamborn	Price (NC)	Wamp
			Lampson	Pryce (OH)	Wasserman
			Langevin	Putnam	Schultz
			Larsen (WA)	Radanovich	Waters
			Larson (CT)	Rahall	Watson
			Latham	Ramstad	Watt
			LaTourette	Rangel	Waxman
			Latta	Regula	Weiner
			Lee	Rehberg	Welch (VT)
			Levin	Reichert	Weller
			Lewis (CA)	Renzi	Westmoreland
			Lewis (GA)	Reyes	Wexler
			Lewis (KY)	Reynolds	Wilson (NM)
			Linder	Richardson	Wilson (OH)
			Lipinski	Rodriguez	Wilson (SC)
			LoBiondo	Rogers (AL)	Wittman (VA)
			Loeb	Rogers (KY)	Wolf
			Lofgren, Zoe	Rogers (MI)	Woolsey
			Lowey	Rohrabacher	Wu
			Lucas	Ros-Lehtinen	Yarmuth
			Lungren, Daniel	Roskam	Young (AK)
			E.	Ross	Young (FL)

NAYS—1

Paul

NOT VOTING—18

Bachus	Everett	Napolitano
Boehner	Frank (MA)	Shuler
Conyers	Hastings (FL)	Souder
Cramer	Hoyer	Udall (CO)
Cubin	Israel	Weldon (FL)
Davis, David	Miller (FL)	Whitfield (KY)

□ 1604

Mrs. BACHMANN changed her vote from “nay” to “yea.”

So (two-thirds being in the affirmative) the rules were suspended and the concurrent resolution, as amended, was agreed to.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

Stated for:

Mr. BACHUS. Madam Speaker, on September 25, 2008, I missed rollcall vote 641 while attending a meeting at the White House to discuss the Nation's financial crisis. Had I been present, I would have voted “yea” on rollcall 641.

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore (Ms. BALDWIN). Pursuant to clause 8 of rule XX, the Chair will postpone further proceedings today on motions to suspend the rules on which a recorded vote or the yeas and nays are ordered, or on which the vote is objected to under clause 6 of rule XX.

Record votes on postponed questions will be taken later today.

BREAST CANCER AND ENVIRONMENTAL RESEARCH ACT OF 2008

Mr. PALLONE. Madam Speaker, I move to suspend the rules and pass the bill (H.R. 1157) to amend the Public Health Service Act to authorize the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer, as amended.

The Clerk read the title of the bill.

The text of the bill is as follows:

H.R. 1157

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Breast Cancer and Environmental Research Act of 2008”.

SEC. 2. EXPANDING COLLABORATIVE RESEARCH ON BREAST CANCER AND THE ENVIRONMENT.

(a) *IN GENERAL.*—Subpart 1 of part C of title IV of the Public Health Service Act (42 U.S.C. 285 et seq.) is amended by adding at the end the following:

“SEC. 417F. INTERAGENCY BREAST CANCER AND ENVIRONMENTAL RESEARCH COORDINATING COMMITTEE.

“(a) *INTERAGENCY BREAST CANCER AND ENVIRONMENTAL RESEARCH COORDINATING COMMITTEE.*—

“(1) *ESTABLISHMENT.*—Not later than 6 months after the date of the enactment of this section, the Secretary shall establish a committee, to be known as the Interagency Breast

Cancer and Environmental Research Coordinating Committee (in this section referred to as the ‘Committee’).

“(2) *DUTIES.*—The Committee shall—

“(A) *share and coordinate information on existing research activities, and make recommendations to the National Institutes of Health and other Federal agencies regarding how to improve existing research programs, that are related to breast cancer research;*

“(B) *develop a comprehensive strategy and advise the National Institutes of Health and other Federal agencies in the solicitation of proposals for collaborative, multidisciplinary research, including proposals to evaluate environmental and genomic factors that may be related to the etiology of breast cancer that would—*

“(i) *result in innovative approaches to study emerging scientific opportunities or eliminate knowledge gaps in research to improve the research portfolio;*

“(ii) *outline key research questions, methodologies, and knowledge gaps;*

“(iii) *expand the number of research proposals that involve collaboration between 2 or more national research institutes or national centers, including proposals for Common Fund research described in section 402(b)(7) to improve the research portfolio; and*

“(iv) *expand the number of collaborative, multidisciplinary, and multi-institutional research grants;*

“(C) *develop a summary of advances in breast cancer research supported or conducted by Federal agencies relevant to the diagnosis, prevention, and treatment of cancer and other diseases and disorders; and*

“(D) *not later than 2 years after the date of the establishment of the Committee, make recommendations to the Secretary—*

“(i) *regarding any appropriate changes to research activities, including recommendations to improve the research portfolio of the National Institutes of Health to ensure that scientifically-based strategic planning is implemented in support of research priorities that impact breast cancer research activities;*

“(ii) *to ensure that the activities of the National Institutes of Health and other Federal agencies, including the Department of Defense, are free of unnecessary duplication of effort;*

“(iii) *regarding public participation in decisions relating to breast cancer research to increase the involvement of patient advocacy and community organizations representing a broad geographical area;*

“(iv) *on how best to disseminate information on breast cancer research progress; and*

“(v) *on how to expand partnerships between public entities, including Federal agencies, and private entities to expand collaborative, cross-cutting research.*

“(3) *RULE OF CONSTRUCTION.*—For the purposes of the Committee, when focusing on research to evaluate environmental and genomic factors that may be related to the etiology of breast cancer, nothing in this section shall be construed to restrict the Secretary from including other forms of cancer, as appropriate, when doing so may advance research in breast cancer or advance research in other forms of cancer.

“(4) *MEMBERSHIP.*—

“(A) *IN GENERAL.*—The Committee shall be composed of the following voting members:

“(i) *Not more than 7 voting Federal representatives as follows:*

“(I) *The Director of the Centers for Disease Control and Prevention.*

“(II) *The Director of the National Institutes of Health and the directors of such national research institutes and national centers (which may include the National Institute of Environmental Health Sciences) as the Secretary determines appropriate.*

“(III) *One representative from the National Cancer Institute Board of Scientific Advisors, appointed by the Director of the National Cancer Institute.*

“(IV) *The heads of such other agencies of the Department of Health and Human Services as the Secretary determines appropriate.*

“(V) *Representatives of other Federal agencies that conduct or support cancer research, including the Department of Defense.*

“(ii) *12 additional voting members appointed under subparagraph (B).*

“(B) *ADDITIONAL MEMBERS.*—The Committee shall include additional voting members appointed by the Secretary as follows:

“(i) *6 members shall be appointed from among scientists, physicians, and other health professionals, who—*

“(I) *are not officers or employees of the United States;*

“(II) *represent multiple disciplines, including clinical, basic, and public health sciences;*

“(III) *represent different geographical regions of the United States;*

“(IV) *are from practice settings, academia, or other research settings; and*

“(V) *are experienced in scientific peer review process.*

“(ii) *6 members shall be appointed from members of the general public, who represent individuals with breast cancer.*

“(C) *NONVOTING MEMBERS.*—The Committee shall include such nonvoting members as the Secretary determines to be appropriate.

“(5) *CHAIRPERSON.*—The voting members of the Committee shall select a chairperson from among such members. The selection of a chairperson shall be subject to the approval of the Director of NIH.

“(6) *MEETINGS.*—The Committee shall meet at the call of the chairperson of the Committee or upon the request of the Director of NIH, but in no case less often than once each year.

“(b) *REVIEW.*—The Secretary shall review the necessity of the Committee in calendar year 2011 and, thereafter, at least once every 2 years.”.

(b) *AUTHORIZATION OF APPROPRIATIONS.*—For the purpose of carrying out research activities under title IV of the Public Health Service Act, including section 417F of such Act as added by subsection (a), there are authorized to be appropriated \$40,000,000 for each of fiscal years 2009 through 2012. Amounts authorized to be appropriated under the preceding sentence shall be in addition to amounts otherwise authorized to be appropriated for such purpose under section 402A of the Public Health Service Act (42 U.S.C. 282a).

The SPEAKER pro tempore. Pursuant to the rule, the gentleman from New Jersey (Mr. PALLONE) and the gentleman from Georgia (Mr. DEAL) each will control 20 minutes.

The Chair recognizes the gentleman from New Jersey.

GENERAL LEAVE

Mr. PALLONE. Madam Speaker, I ask unanimous consent that all Members may have 5 legislative days to revise and extend their remarks and include extraneous material on the bill under consideration.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from New Jersey?

There was no objection.

Mr. PALLONE. Madam Speaker, I yield myself such time as I may consume.

Madam Speaker, I rise in strong support of H.R. 1157, the Breast Cancer and Environmental Research Act, legislation introduced by Representatives NITA LOWEY and SUE MYRICK.

According to the Centers for Disease Control and Prevention, the CDC, breast cancer is the second most common form of cancer in women. Each